Stifel Nicolaus Trims Envista (NYSE:NVST) Target Price to $50.00

Envista (NYSE:NVSTGet Rating) had its target price reduced by stock analysts at Stifel Nicolaus from $55.00 to $50.00 in a research report issued on Friday, The Fly reports. Stifel Nicolaus’ target price would indicate a potential upside of 39.98% from the stock’s previous close.

A number of other research firms have also commented on NVST. Piper Sandler lowered their price target on Envista from $50.00 to $49.00 in a research report on Thursday, May 5th. Morgan Stanley increased their price target on Envista from $52.00 to $56.00 and gave the company an “overweight” rating in a research report on Monday, April 4th. Finally, Robert W. Baird lowered Envista from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $54.00 to $46.00 in a research report on Tuesday.

Shares of NVST opened at $35.72 on Friday. Envista has a 12-month low of $35.24 and a 12-month high of $52.03. The business’s fifty day moving average is $42.42 and its 200 day moving average is $44.24. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.22. The stock has a market cap of $5.81 billion, a P/E ratio of 18.51, a P/E/G ratio of 1.38 and a beta of 1.63.

Envista (NYSE:NVSTGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.03. Envista had a return on equity of 8.54% and a net margin of 13.06%. The company had revenue of $631.40 million for the quarter, compared to analysts’ expectations of $629.30 million. During the same period last year, the business earned $0.54 EPS. Envista’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, analysts expect that Envista will post 2.02 EPS for the current year.

In related news, CFO Howard H. Yu sold 5,341 shares of Envista stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $45.73, for a total value of $244,243.93. Following the completion of the sale, the chief financial officer now owns 52,411 shares of the company’s stock, valued at approximately $2,396,755.03. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Amir Aghdaei sold 10,538 shares of Envista stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $51.66, for a total value of $544,393.08. The disclosure for this sale can be found here. Company insiders own 0.76% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Midwest Wealth Management Inc. increased its holdings in Envista by 6.6% in the 1st quarter. Midwest Wealth Management Inc. now owns 40,475 shares of the company’s stock worth $1,972,000 after acquiring an additional 2,499 shares during the last quarter. Virtu Financial LLC boosted its stake in Envista by 111.6% in the 1st quarter. Virtu Financial LLC now owns 9,445 shares of the company’s stock worth $460,000 after purchasing an additional 4,981 shares during the period. Alyeska Investment Group L.P. bought a new position in Envista in the 1st quarter worth about $36,982,000. Point72 Hong Kong Ltd bought a new position in Envista in the 1st quarter worth about $1,812,000. Finally, Sandler Capital Management bought a new position in Envista in the 1st quarter worth about $8,305,000.

Envista Company Profile (Get Rating)

Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands.

Read More

The Fly logo

Want More Great Investing Ideas?

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.